We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dako to Collaborate with Merck
News

Dako to Collaborate with Merck

Dako to Collaborate with Merck
News

Dako to Collaborate with Merck

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dako to Collaborate with Merck"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dako announce today it has entered into a master framework agreement with Merck to develop companion diagnostic tests for oncology drugs currently in Merck’s development pipeline.

"Dako is relentless in its commitment to fighting cancer, together with our customers and pharma partners," said Jacob Thaysen, vice president and general manager for Agilent's Diagnostics and Genomics business. "With Dako’s wide experience in companion diagnostics and its expanded playing field as part of Agilent’s Life Sciences and Diagnostics Group, I see great potential in this new agreement. I warmly welcome Merck as our new partner."

The market for companion diagnostics is steadily growing, as personalized medicine may improve patient care and manage healthcare costs by targeting treatments to individuals more likely to benefit from specific therapies.

Dako collaborates with many top-tier pharma companies to develop companion diagnostics, with a record of successful long-term partnerships with companies such as Bristol-Myers Squibb and Genentech, a member of the Roche Group. Dako continues to attract new partners, most recently Eli Lilly, Pfizer and now Merck.

The financial terms of the master framework agreement were not disclosed.

Advertisement